Skip to main content

USPTO Examination Guidelines for Determining Obviousness Under 35 U.S.C. 103

The guidelines aim to help patent examiners assess whether an invention is non-obvious, which is a key requirement for obtaining a patent.


The determination of obviousness involves a legal analysis of whether the claimed invention, as a whole, would have been obvious to a person having ordinary skill in the art at the time the invention was made, based on the prior art available. The MPEP outlines several steps that examiners should follow:


1. Identify the Prior Art: The examiner must locate and consider the relevant prior art that existed before the filing date of the patent application. Prior art includes patents, published patent applications, scientific publications, and other publicly available materials.


2. Determine the Differences: The examiner needs to identify the differences between the claimed invention and the prior art. These differences are known as the "claimed invention features" and are used as a basis for the obviousness analysis.


3. Establish the Level of Ordinary Skill: Examiners must define the level of ordinary skill in the art at the time of the invention. This is a hypothetical person who possesses the average knowledge and skills of practitioners in the relevant field.


4. Assess the Scope and Content of the Prior Art: The examiner evaluates the relevant prior art to understand the state of the technology and the range of information available to the person of ordinary skill.


5. Determine the Motivation to Combine: The examiner considers whether a person of ordinary skill would have been motivated to combine the elements of the prior art to arrive at the claimed invention. Motivation can be explicit (suggested in the prior art) or implicit (based on common knowledge and design incentives).


6. Evaluate Secondary Considerations: Examiners may consider "secondary considerations" or objective indicia of non-obviousness. These include evidence of commercial success, long-felt but unresolved need, unexpected results, and others.


7. Make a Conclusion: Based on the analysis of the above factors, the examiner determines whether the claimed invention would have been obvious or non-obvious to a person of ordinary skill in the art.


It's important to note that the determination of obviousness is a subjective judgment based on the available evidence, and different examiners may reach different conclusions. Applicants can present arguments and evidence to support the non-obviousness of their invention during the patent prosecution process.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys